Business Context and Reporting Period
This Form 6-K is filed by Adherex Technologies Inc. (noted as Fennec Pharmaceuticals Inc. in metadata) on January 19, 2007. The filing reports a material event occurring on January 18, 2007, involving a third amendment to a development and license agreement with Glaxo Group Limited, originally executed on July 14, 2005.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the legal amendment of a corporate agreement and does not contain financial statements or performance metrics.
Material Changes
- Agreement Amendment: The Company entered into a third amendment to its development and license agreement with Glaxo Group Limited.
- Documentation: The amendment is dated January 17, 2007, and a press release announcing the event was issued on January 18, 2007.
- Regulatory Filing: A material change report was filed in Canada under National Instrument 51-102 regarding these events.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, or specific risk factors related to the amendment. The document explicitly states that the information contained herein is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 4.42 (Amendment No. 3) to understand the specific terms modified in the Glaxo Group Limited agreement.
- Examine Exhibit 99.1 (Press Release) for details on the strategic impact of the amendment.
- Verify the status of the original July 14, 2005, agreement to assess the cumulative effect of this third amendment.
- Confirm that no financial obligations or milestones were triggered by this specific amendment, as no financial data is disclosed in this filing.